Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Immutep ( (IMMP) ) just unveiled an announcement.
Immutep Limited reported its preliminary financial results for the year ended June 30, 2025, on August 29, 2025. The company experienced an increase in losses, with a loss after tax rising from $42.7 million in FY2024 to $61.4 million in FY2025. This increase was primarily due to a $19.9 million rise in R&D and intellectual property expenses, largely driven by higher clinical trial costs. Despite the financial loss, the company saw a rise in other income and interest income, attributed to higher cash balances invested in term deposits. The report highlights the company’s ongoing commitment to advancing its clinical trials, although it did not declare any dividends for the period.
The most recent analyst rating on (IMMP) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Immutep stock, see the IMMP Stock Forecast page.
Spark’s Take on IMMP Stock
According to Spark, TipRanks’ AI Analyst, IMMP is a Neutral.
Immutep’s overall stock score reflects the challenges and potential of a biotech firm in its developmental stage. Strong financial stability from a robust balance sheet is offset by negative profitability and cash flow. Technical analysis provides some optimism with balanced momentum signals, but valuation remains a concern due to ongoing losses. This score highlights the high-risk, high-reward nature of investing in early-stage biotech stocks.
To see Spark’s full report on IMMP stock, click here.
More about Immutep
Immutep Limited is a biotechnology company based in Sydney, Australia, specializing in the development of immunotherapy treatments for cancer and autoimmune diseases. The company focuses on leveraging its expertise in LAG-3 (Lymphocyte Activation Gene-3) to develop innovative therapies that enhance the immune system’s ability to fight disease.
Average Trading Volume: 83,075
Technical Sentiment Signal: Sell
Current Market Cap: $220.3M
Find detailed analytics on IMMP stock on TipRanks’ Stock Analysis page.